Overview
Bruton's tyrosine kinase (BTK) is abundantly expressed in B cell leukemias and lymphomas. Small molecule BTK inhibitors have proved efficacious in this space and clinical development of this therapeutic strategy is ongoing and rapidly evolving.
This activity will update oncology health care professionals on the most recent data from key abstracts focusing on BTK inhibition in B-cell leukemia and lymphoma that were presented at recent summer 2023 meetings. By placing the data in clinical context, oncology practitioners can assess and apply these findings to their clinical practice and ultimately improve care for their patients with B-cell hematologic malignancies.
Learning Objectives:
- Explain the scientific rationale for BTK targeting in the treatment of patients with CLL/SLL and MCL as well as mechanisms of action of covalent and non-covalent BTK inhibitors
- Assess trial design, eligibility criteria, and recent evidence on current and emerging BTK inhibitors investigated in patients with CLL/SLL and MCL
- Evaluate the clinical implications of updated data sets investigating current/emerging BTK inhibitors in patients with CLL/SLL and MCL within the context of evolving treatment algorithms
- Apply proactive strategies to accurately recognize and mitigate the negative impact of treatment-related toxicities associated with BTK inhibition in patients with CLL/SLL and MCL
Target Audience
This educational activity is directed toward hematologists, oncologists, NPs and nurses interested in the treatment of B-cell lymphomas.
Oncology Town Hall™: Post-EHA/ASCO Global Oncology Town Hall Addressing Unmet Needs in R/R CLL/SLL and MCL: Assessing Data for BTK inhibition and Real World Clinical Impact |
|
5 min |
Welcome and Pre-session Survey |
Abstract Presentations: Key Updates with BTK Inhibition |
|
15 min |
Data Presentations: CLL Abstracts |
5 min |
Discussion Panel |
15 min |
Data Presentations: MCL Abstracts |
5 min |
Discussion Panel |
40 min |
Panel Discussion: Applying Recent Evidence and Ongoing Trials to the Care of Your Patients |
5 min |
Closing and Post-session Survey |
Kami Maddocks, MD
Associate Professor of Clinical Internal Medicine
Lymphoma Program Director
Division of Hematology, Department of Internal Medicine
The James Cancer Hospital at The Ohio State University
Columbus, OH
Nicole Lamanna, MD
Associate Professor of Medicine
Leukemia Service
Director of CLL Program
Division of Hematology/Oncology
Columbia University Medical Center
New York, NY
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.